U.S. Department of Defense awarded $2.8 million to UNC Institute for Trauma Recover researchers led by Samuel McLean, MD, to test the safety and efficacy of BXCL501 – sublingual dexmedetomidine created by BioXcel Therapautics for treating acute stress reaction symptoms and preventing posttraumatic stress.
October 15, 2024